[Evaluation of anti-emetic action of domperidone in patients treated with cytostatics].
Domperidone was administered to 40 patients with various neoplastic syndromes to prevent nausea and vomiting observed during previous courses of chemotherapy. It was found, that daily dose of 30 mg completely prevents nausea and vomiting in 30% of patients and significantly lowers such symptoms in further 58% of patients. An increase in a daily dose of 60 mg abolishes nausea and vomiting in 60%, and decrease their intensity in 35% of patients. Domperidone was administered orally during the whole period of chemotherapy without any adverse reactions related to its anti-dopamine actions.
Polubiec
A
A
Katedry i Kliniki Chorób Wewnetrznych i Hematologii II Wydziału Lekarskiego AM w Warszawie.
Krasnopolska-Polańczyk
Z
Z
Duda-Król
W
W
Jórasz
I
I
Witkowski
J
J
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D004294:Domperidone / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D004294:Domperidone
Ocena przeciwwymiotnego działania domperydonu u chorych leczonych cytostatykami.